Plain-English translation of NCT06373055 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
About half of bladder cancer patients don't respond well to platinum-based chemotherapy, which means they endure the side effects without getting the benefit. This study analyzes the genetic and molecular profile of your tumor tissue to predict whether you're likely to respond to this medication. By identifying responders early, doctors can choose the right treatment path for each patient.
Currently, doctors don't have a reliable way to know in advance which patients will benefit from chemotherapy and which won't. This leads some patients to experience harsh side effects and treatment delays without actually benefiting from the medication. This research aims to solve that problem by finding genetic markers that predict treatment response.
You likely qualify if…
You likely don't qualify if…
You will have a standard procedure to remove bladder tissue (transurethral resection), which your doctors likely planned anyway. Researchers will take a small sample of that tissue to analyze its genetic and molecular features. You'll be followed to see how you respond to chemotherapy treatment, allowing researchers to compare your tissue analysis results with your actual treatment outcomes.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
South Korea
Enrollment target
~250 participants
Started
May 2024
Primary completion
November 2033
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in April 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Won Sik Ham
Department of Urology and Urological Science Institute, Yonsei University College of Medicine Seoul, Republic of Korea
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.